Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 1, 1998, Pages 183-191

  Smith, Forrest L ^a   Fujimori, Ken ^a   Lowe, John ^b   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cannabinoid antinociception in rats; Freund's adjuvant arthritis; Mechanical nociception

Indexed keywords

ANANDAMIDE; CANNABINOID; DRONABINOL; FREUND ADJUVANT; RIMONABANT; AMIDE; ANALGESIC AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; DRUG RECEPTOR; OPIATE PEPTIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL MODEL; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; ARTHRITIS, EXPERIMENTAL; CANNABINOIDS; MALE; OPIOID PEPTIDES; PAIN THRESHOLD; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

EID: 0032056333     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00583-2     Document Type: Article

References (51)

1. Adams I. B., Ryan W., Singer M., Razdan R. K., Compton D. R., Martin B. R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56:1995;2041-2048.
2. Collins D. R., Pertwee R. G., Davies S. N. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115:1995;869-870.
3. Colpaert F. C. M., Meert T., De Witte P., Schmitt P. Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat. Life Sci. 31:1982;67-75.
4. 9-tetrahydrocannabinol-induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277:1996;586-594.
5. Compton D. R., Rice K. C., Costa B. R. D., Razdan R. K., Melvin L. S., Johnson M. R., Martin B. R. Cannabinoid structure activity relationship. Correlation of receptor binding and in vivo activities J. Pharmacol. Exp. Ther. 265:1993;218-226.
6. Dahlen S. E., Bjork J., Hedqvist P. Leukotrienes promote plasma leakage and leukocyte adhesion in post capillary venules. In vivo effects with relevance to the acute inflammatory response Proc. Natl. Acad. Sci. USA. 78:1981;3887-3891.
7. De Castro Costa M., De Sutter P., Gybels J., Van Hees J. Adjuvant-induced arthritis in rats. A possible model of chronic pain Pain. 10:1981;173-185.
8. Deutsch D. G., Chin S. A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
9. Devane W. A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA. 91:1994;6698-6701.
10. Devane W. A., Dysarz I. F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
11. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
12. Dixon D. M., Traynor J. R. Formation of [Leu5]-enkephalin from dynorphin. by rat central nervous tissue in vitro J. Neurochem. 54:1990;1379-1385.
13. 9-tetrahydrocannabinol Brain Res. 697:1995;83-90.
14. 9-THC. J. Pharmacol. Exp. Ther. 272:1995;699-707.
15. 2 in the sensitization of mechanoreceptors in normal and inflammed ankle joints of the rat. Exp. Brain Res. 84:1991;383-392.
16. Herzberg U., Eliav E., Bennett G. J., Kopin I. J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
17. Hohmann A. G., Martin W. J., Kang T., Walker J. M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
18. Hollt V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26:1986;59-77.
19. Iadarola M. J., Brady L. S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation. Stimulus specificity, behavioral parameters and opioid binding Pain. 35:1988;313-326.
20. Kruszka K. K., Gross R. W. The ATP- and CoA-independent synthesis of arachidonoylethanolamine. J. Biol. Chem. 269:1994;14345-14348.
21. Lichtman A. H., Martin B. R. Cannabinoid-induced antinociception is mediated by a spinal alpha-2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
22. Lichtman A. H., Cook S. A., Martin B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats. Evidence supporting periaqueductal gray involvement J. Pharmacol. Exp. Ther. 276:1996;585-593.
23. Lyness W. H., Smith F. L., Heavner J. E., Iacono C. U., Garvin R. D. Morphine self-administration in the rat during adjuvant-induced arthritis. Life Sci. 45:1989;2217-2224.
24. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
25. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
26. Melli M. Assessment of plasma leukotriene and prostaglandin levels during adjuvant arthritis and kaolin-induced paw oedema in rats. Prostaglandins Leukot. Essent. Fatty Acids. 33:1988;173-178.
27. Millan M. J., Czlonkowski A., Morris B., Stein C., Arendt R., Huber A., Hollt V., Herz A. Inflammation of the hind-limb as a model of unilateral, localized pain. Influence on multiple opioid systems in the spinal cord of the rat Pain. 35:1988;299-312.
28. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
29. Nahin R. L., Hylden J. L., Iadarola M. J., Dubner R. Peripheral inflammation is associated with increased dynorphin immunoreactivity in both projection and local circuit neurons in the superficial dorsal horn of the rat lumbar spinal cord. Neurosci. Lett. 96:1989;247-521.
30. Panetta J. A., Benslay D. N., Phillips M. L., Towner R. D., Wang B. L., Ho P. P. K. The antiinflammatory effects of LY178002 and LY256548. Agents Actions. 27:1989;300-302.
31. Panetta J. A., Benslay D. N., Shadle J. K., Towner R. D., Ho P. P. K. Antiinflammatory effects of LY221068 and LY269415. Agents Actions. 34:1991;100-102.
32. Przewlocka B., Lason W., Przewlocki R. Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats - A release and in situ hybridization study. Neuroscience. 46:1992;209-216.
33. 9-THC in the spinal cord. Brain Res. 689:1995;157-158.
34. 9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
35. Randall L. O., Sellito J. J. A method for measurement of analgesic activity on inflammed tissue. Arch. Int. Pharmacodyn. 111:1957;409-419.
36. Richardson J., Aanonsen L., Hargreaves K. M. SR141716A, A cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;3R-5R.
37. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra R., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J. C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
38. Showalter V. M., Compton D. R., Martin B. R., Abood M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2). Identification of cannabinoid receptor subtype selective ligands J. Pharmacol. Exp. Ther. 278:1996;989-999.
39. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
40. 9-tetrahydrocannabinol (THC). J. Pharmacol. Exp. Ther. 186:1973;646-655.
41. Stein C., Millan M. J., Yassouridis A., Herz A. Antinociceptive effects of mu and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur. J. Pharmacol. 155:1988;255-264.
42. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Waku K. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis. Ivolvement of Ca(2+)-dependent transacylase and phosphodiesterase activities Biochem. Biophys. Res. Commun. 218:1996;113-117.
43. Tallarida R. J., Murray R. B. Manual of pharmacologic calculations with computer programs. 2:1987;Springer Verlag, New York.
44. 9-THC-DMH. J. Pharmacol. Exp. Ther. 263:1991;1383-1390.
45. Welch S. P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine, but not by N,N-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
46. Welch S. P. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol. Biochem. Behav. 49:1994;929-934.
47. 9-THC-induced interactions with dynorphinergic systems Drug Alcohol Depend. 45:1997;39-45.
48. 9-THC-induced antinociception J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
49. Welch S. P., Thomas C., Patrick G. S. Modulation of cannabinoid-induced antinociception following intracerebroventricular vs. intrathecal administration to mice. Possible mechanisms for interaction with morphine J. Pharmacol. Exp. Ther. 272:1995;310-321.
50. 9-THC release spinal dynorphin or leu-enkephalin in vivo in rats. NIDA Res. Monogr. (in press).
51. Wiley J. L., Barrett R. L., Lowe J., Balster R. L., Martin B. R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669-676.